Sara Elizabeth Maloney

Dr. Sara Elizabeth Maloney

RTI International, Durham, California, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2019 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
MMMaggie J. Malone‐Povolny
Maggie J. Malone‐Povolny
Sara Elizabeth MaloneySara Elizabeth Maloney
Sara Elizabeth Maloney
MSMark H. Schoenfisch
Mark H. Schoenfisch

29 December 2020 in Biomacromolecules
Verified
Journal Article
Closed access
Sara Elizabeth MaloneySara Elizabeth Maloney
Sara Elizabeth Maloney
KMKyle V. McGrath
Kyle V. McGrath
MAMona Jasmine R. Ahonen
Mona Jasmine R. Ahonen
DSDaniel S. Soliman
Daniel S. Soliman
EFEvan S. Feura
Evan S. Feura
MSMark H. Schoenfisch
Mark H. Schoenfisch

17 May 2022 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
Sara Elizabeth MaloneySara Elizabeth Maloney
Sara Elizabeth Maloney
CBChristopher A. Broberg
Christopher A. Broberg
QGQuincy E. Grayton
Quincy E. Grayton
SPSamantha L. Picciotti
Samantha L. Picciotti
HHHannah R. Hall
Hannah R. Hall
MSMark H. Schoenfisch
Mark H. Schoenfisch

1 April 2024 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
Verified
Journal Article
Closed access
AHAnthony J. Hickey
Anthony J. Hickey
Sara Elizabeth MaloneySara Elizabeth Maloney
Sara Elizabeth Maloney
PKPhillip J. Kuehl
Phillip J. Kuehl
JPJonathan E. Phillips
Jonathan E. Phillips
RWRonald K. Wolff
Ronald K. Wolff
Animal studies are an important component of drug product development and the regulatory review process since modern practices have been in place, for almost a century. A variety of experimental systems are available to generate aerosols for delivery to animals in both liquid and solid forms. The extrapolation of deposited dose in the lungs from laboratory animals to humans is challenging because of genetic, anatomical, physiological, pharmacological, and other biological differences between species. Inhaled drug delivery extrapolation requires scrutiny as the aerodynamic behavior, and its role in lung deposition is influenced not only by the properties of the drug aerosol but also by the anatomy and pulmonary function of the species in which it is being evaluated. Sources of variability between species include the formulation, delivery system, and species-specific biological factors. It is important to acknowledge the underlying variables that contribute to estimates of dose scaling between species.

4 December 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Sara Elizabeth MaloneySara Elizabeth Maloney
Sara Elizabeth Maloney
LLLeanna Page Kantt Levin
Leanna Page Kantt Levin
AHAnthony J Hickey
Anthony J Hickey
DHDavid B. Hill
David B. Hill
Natural and synthetic biopolymers are gaining popularity in the development of inhaled drug formulations. Their highly tunable properties and ability to sustain drug release allow for the incorporation of attributes not achieved in dry powder inhaler formulations composed only of micronized drugs, standard excipients, and/or carriers. There are multiple physiological barriers to the penetration of inhaled drugs to the epithelial surface, such as the periciliary layer mucus mesh, pulmonary macrophages, and inflammation and mucus compositional changes resulting from respiratory diseases. Biopolymers may facilitate transport to the epithelial surface despite such barriers. A variety of categories of biopolymers have been assessed for their potential in inhaled drug formulations throughout the research literature, ranging from natural biopolymers (e.g., chitosan, alginate, hyaluronic acid) to those synthesized in a laboratory setting (e.g., polycaprolactone, poly(lactic-co-glycolic acid)) with varying structures and compositions. To date, no biopolymers have been approved as a commercial dry powder inhaler product. However, advances may be possible in the treatment of respiratory diseases and infections upon further investigation and evaluation. Herein, this review will provide a thorough foundation of reported research utilizing biopolymers in dry powder inhaler formulations. Furthermore, insight and considerations for the future development of dry powder formulations will be proposed.

10 January 2023 in KONA Powder and Particle Journal
Verified
Journal Article
Open access
PDF file
Sara Elizabeth MaloneySara Elizabeth Maloney
Sara Elizabeth Maloney
JMJeffrey B. Mecham
Jeffrey B. Mecham
AHAnthony J. Hickey
Anthony J. Hickey
It is well established that the critical performance metrics for aerosol products are aerodynamic particle size distribution (APSD) and delivered dose uniformity (DDU). In broad terms, these performance characteristics dictate the efficiency and reproducibility with which an aerosol is administered clinically. However, these properties alone do not support in-vitro, in-vivo correlations. There have been numerous publications attempting to more directly link product performance testing to physiological relevance or further to draw direct correlations of relevance to bioequivalence testing for the development of generic products. While these novel methods have been employed in product development activity, their suitability for compendial testing has yet to be established. This paper explores the potential to establish biologically relevant compendial standards for dry powder inhaler products while maintaining accuracy and reproducibility of data collected to support the quality and performance of the product.